Cetin Türkan, Oğuz Arzu, Algan Pelin, Yildirim I Safa
3. Internal Medicine Clinic, SSK Ankara Education Hospital, Ankara, Turkey.
Turk J Gastroenterol. 2003 Sep;14(3):177-80.
BACKGROUND/AIMS: Tissue polypeptide specific antigen was first defined by Bjorklund in 1957 and is the specific M3 epitope of tissue polypeptide antigen. It is increased in malignant as well as in some benign diseases. The level of tissue polypeptide specific antigen in serum is related mostly with proliferation capacity rather than with tumor mass and cell necrosis. The aim of this study was to evaluate the levels of tissue polypeptide specific antigen and other tumor markers in patients with liver cirrhosis, chronic active hepatitis and hepatoma to determine if tissue polypeptide specific antigen is superior to other tumor markers in hepatoma patients.
Thirty-seven patients and 20 controls were included in the study. The patients were divided into three subgroups as cirrhosis, hepatoma and chronic active hepatitis. The levels of tissue polypeptide specific antigen, carcinoembryonic antigen, CA19-9, alpha-fetoprotein and transaminases were determined in all patients.
Tissue polypeptide specific antigen levels were significantly higher in all patients than in the control group (p<0.005) According to Kruskal-Wallis test with regard to subgroups, the differences in mean values of tissue polypeptide specific antigen and alpha-fetoprotein were highly significant (p: 0.0001 for both). There was a low correlation between tissue polypeptide specific antigen and alpha-fetoprotein in the cirrhotic and hepatoma groups, but these were significantly correlated in the chronic active hepatitis group. The correlation coefficient between tissue polypeptide specific antigen and transaminases in all patients was low.
Our data suggest that tissue polypeptide specific antigen is efficient in determining primary hepatoma patients and also that this marker is specific for proliferation of cells.
背景/目的：组织多肽特异性抗原于1957年由比约克隆德首次定义，是组织多肽抗原的特异性M3表位。它在恶性疾病以及一些良性疾病中都会升高。血清中组织多肽特异性抗原的水平主要与增殖能力相关，而非与肿瘤大小和细胞坏死相关。本研究的目的是评估肝硬化、慢性活动性肝炎和肝癌患者的组织多肽特异性抗原及其他肿瘤标志物水平，以确定组织多肽特异性抗原在肝癌患者中是否优于其他肿瘤标志物。
本研究纳入了37例患者和20例对照。患者被分为肝硬化、肝癌和慢性活动性肝炎三个亚组。测定了所有患者的组织多肽特异性抗原、癌胚抗原、CA19-9、甲胎蛋白和转氨酶水平。
所有患者的组织多肽特异性抗原水平均显著高于对照组（p<0.005）。根据Kruskal-Wallis检验，关于亚组，组织多肽特异性抗原和甲胎蛋白的平均值差异高度显著（两者p值均为0.0001）。在肝硬化组和肝癌组中，组织多肽特异性抗原与甲胎蛋白之间的相关性较低，但在慢性活动性肝炎组中两者显著相关。所有患者中组织多肽特异性抗原与转氨酶之间的相关系数较低。
我们的数据表明，组织多肽特异性抗原在确定原发性肝癌患者方面是有效的，并且该标志物对细胞增殖具有特异性。
Zotero 插件